SCHEMBL4833604

SCHEMBL4833604

NC1c2ccsc2N=CN1c1ccc(NC(=O)Cc2c(F)cccc2F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 2/20 0.44
▸ LMNA P02545 1/20 0.42
▸ DNMT3B Q9UBC3 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ POLB P06746 3/20 0.37
▸ NPC1 O15118 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ GLS O94925 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ PDE4A P27815 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826966 0.85 JAK2 (0.43) LMNASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL4836549 0.85 RAB9A (0.46) MAPK8SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL4833950 0.77 GRM5 (0.41) LMNASMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL4828954 0.69 POLB (0.49) SMN1; SMN2POLBNPC1RAB9AKMT2A
SCHEMBL4831557 0.69 BTK (0.49) RAB9AGLSMAPT
SCHEMBL4833596 0.68 MAPK8 (0.45) MAPK8LMNADNMT3BSMN1; SMN2POLB
SCHEMBL5639552 0.65 SMN1; SMN2 (0.81) MAPK8LMNADNMT3BSMN1; SMN2POLB
SCHEMBL7023940 0.58 MAPK8 (0.53) MAPK8DNMT3BSMN1; SMN2NPC1RAB9A
SCHEMBL24173209 0.58 SMN1; SMN2 (1.00) LMNADNMT3BSMN1; SMN2POLBNPC1
SCHEMBL20485737 0.58 ELOVL1 (0.77) LMNASMN1; SMN2NPC1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPK8 1029/4885LMNA 4230/4885DNMT3B 334/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPK8 2025/4885LMNA 4131/4885DNMT3B 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback